Suppr超能文献

反复给予间氯苯哌嗪或1-(2,5-二甲氧基-4-碘苯基)-2-氨基丙烷会使大鼠对其对促肾上腺皮质激素的刺激作用产生耐受性,但对催乳素或皮质酮分泌则无耐受性。

Repeated administration of meta-chlorophenylpiperazine or 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane produces tolerance to its stimulatory effect on adrenocorticotropin hormone but not prolactin or corticosterone secretion in rats.

作者信息

Mazzola-Pomietto P, Aulakh C S, Huang S J, Murphy D L

机构信息

Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Maryland, USA.

出版信息

J Pharmacol Exp Ther. 1996 Nov;279(2):782-9.

PMID:8930184
Abstract

In an attempt to clarify whether m-chlorophenylpiperazine-(m-CPP) and 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane-(DOI) induced increases in plasma adrenocorticotropin hormone, corticosterone and prolactin secretion are mediated by the same or different mechanisms, we studied the time course of development of tolerance to the neuroendocrine effects of m-CPP (2.5 mg/kg/day) and DOI (2.5 mg/kg/day) in rats and, furthermore, also evaluated possible cross-tolerance in responses to m-CPP and DOI. We observed the development of tolerance in adrenocorticotropin hormone responses after a single i.p. injection of m-CPP. However, there was no cross-tolerance to DOI when chronic (13 days) m-CPP-treated animals were challenged with DOI (2.5 mg/kg). Injections of DOI (2.5 mg/kg) for six days were required before tolerance developed to the effect of DOI on adrenocorticotropin hormone. Furthermore, cross-tolerance was observed when DOI-treated animals (2.5 mg/kg/day x 6) were challenged with m-CPP (2.5 mg/kg) on day 7. In contrast, daily administration of m-CPP and DOI for 13 days did not produce tolerance to their stimulating effects on corticosterone and prolactin secretion. Hypothalamic levels of 5-hydroxyindoleacetic acid but not 5-HT were significantly reduced after acute or subchronic administration of both m-CPP and DOI. Furthermore, no change in the approximate 50% reduction in 5-hydroxyindoleacetic acid after m-CPP was observed after subchronic administration of this drug. These findings suggest that separate mechanisms mediate m-CPP and DOI-induced adrenocorticotropin hormone secretion in rats.

摘要

为了阐明间氯苯哌嗪(m-CPP)和1-(2,5-二甲氧基-4-碘苯基)-2-氨基丙烷(DOI)诱导的血浆促肾上腺皮质激素、皮质酮和催乳素分泌增加是由相同还是不同机制介导的,我们研究了大鼠对m-CPP(2.5毫克/千克/天)和DOI(2.5毫克/千克/天)神经内分泌效应耐受性的发展时间进程,此外,还评估了对m-CPP和DOI反应中可能存在的交叉耐受性。我们观察到单次腹腔注射m-CPP后促肾上腺皮质激素反应中耐受性的发展。然而,当用DOI(2.5毫克/千克)对慢性(13天)m-CPP处理的动物进行激发时,对DOI没有交叉耐受性。在对DOI对促肾上腺皮质激素的作用产生耐受性之前,需要连续六天注射DOI(2.5毫克/千克)。此外,在第7天用m-CPP(2.5毫克/千克)对DOI处理的动物(2.5毫克/千克/天×6)进行激发时,观察到了交叉耐受性。相比之下,连续13天每日给予m-CPP和DOI并未使其对皮质酮和催乳素分泌的刺激作用产生耐受性。急性或亚慢性给予m-CPP和DOI后,下丘脑5-羟吲哚乙酸水平显著降低,但5-羟色胺水平未降低。此外,亚慢性给予该药物后,未观察到m-CPP后5-羟吲哚乙酸约50%的降低有变化。这些发现表明,大鼠中m-CPP和DOI诱导的促肾上腺皮质激素分泌由不同机制介导。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验